FORA Capital’s Enanta Pharmaceuticals ENTA Stock Holding History

FORA Capital’s Portfolio ENTA Stock Details ENTA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q2	–	Sell	-626	Closed	-$32K	–	1017
2020 Q1	$32K	Buy	+626	New	+$33.4K	0.01%	871

Other funds holding ENTA

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

KAM

Krensavage Asset Management New York $256M AUM 69.63% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

FORA Capital's ENTA Position: Q2 2020 in Review

FORA Capital sold out of Enanta Pharmaceuticals (ENTA) in Q2 2020, closing a stake of 626 shares — an estimated $32K sold.

FORA Capital first reported a position in ENTA in Q1 2020 and held it in 1 quarter. The position peaked at $32K in Q1 2020. 180 funds tracked by Wall St. Rank hold ENTA as of Q2 2020.

FORA Capital reported no remaining Enanta Pharmaceuticals position as of Q2 2020 after selling out during the quarter.
FORA Capital sold 626 Enanta Pharmaceuticals shares in Q2 2020, an estimated $32K.
FORA Capital first reported a position in Enanta Pharmaceuticals in Q1 2020 and held it in 1 quarter.
FORA Capital's Enanta Pharmaceuticals position peaked at $32K in Q1 2020.
180 funds tracked by Wall St. Rank held Enanta Pharmaceuticals as of Q2 2020.

Based on FORA Capital's 13F filing for Q2 2020, filed 14 Aug 2020.